Device-Activated Drugs, An Old Dog With Some New Tricks
As technologies move from the lab to commercialization, changes to them need to be made to make them financially and practically appropriate for clinical settings. In Vivo spoke to two companies pioneering new types of device-activated drugs to learn about these changes and how the end products will help patients.
You may also be interested in...
Medtech Insight's Approvals Tracker reports 22 medical device approvals from outside the United States in November, including 12 CE marks from Europe, plus approvals from Taiwan, Singapore, Japan, India, Canada, Australia and Argentina.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Less than a month after it sold off its reproductive health assets, Invitae has filed for bankruptcy. That will not come as a surprise to anyone following the company.